Benchmarking Rare Disease Field Medical Excellence in APAC: Establishing Standards for High Performance & Impact

KEY TOPICS

• Effective Rare Disease Field Performance Metrics in the APAC Region
• Building a Rare Disease Field Medical Excellence Framework
• Target and Engagement Levels of Rare Disease KOLs in the APAC Region
• Average Time Spent by Rare Disease MSLs on KOL Interactions and Internal Activities in the APAC Region
• Rare Disease Field Medical Staffing Footprint in the APAC Region
• Key Insights and Lessons Learned for Measuring the Impact of Rare Disease MSLs in the APAC Region

• Asia-Pacific field scorecard: Benchmarking rare disease engagements
• Average total panel size supported by an individual rare disease MSL in the APAC region
• Average number of monthly KOL/HCP and F2F meetings in the APAC region – Rare disease segment
• Value assigned to each interaction type on the rare disease MSL scorecard (APAC)
• Engagement metrics for non-tiered rare disease KOLs in the APAC region
• Average annual field presence of rare disease MSLs in the APAC region
• Time spent by rare disease MSLs on external, internal, and logistics activities in the APAC region
• Weekly rare disease MSL time allocation across activity streams in the APAC region
• Rare disease MSL engagement mix in the APAC region
• Rare disease field medical staffing footprint in the APAC region

• Metrics for Engaging Non-Tiered Rare Disease KOLs in the APAC Region: Rare diseases manufacturers from the APAC region do not employ special metrics for measuring non-tiered KOL engagements. Meanwhile, across all therapeutic areas, 40% of companies employ special metrics to assess the engagement of non-tiered KOLs.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.